Bar-On P - Search Results

1

Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.

Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E. Bar-On P, et al. J Neurochem. 2008 Jun;105(5):1656-67. doi: 10.1111/j.1471-4159.2008.05254.x. Epub 2008 Jan 28. J Neurochem. 2008. PMID: 18248604 Free PMC article.

2

Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.

Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L, Masliah E. Hashimoto M, et al. Among authors: bar on p. J Biol Chem. 2004 May 28;279(22):23622-9. doi: 10.1074/jbc.M313784200. Epub 2004 Mar 16. J Biol Chem. 2004. PMID: 15026413 Free article.

3

The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.

Hashimoto M, Kawahara K, Bar-On P, Rockenstein E, Crews L, Masliah E. Hashimoto M, et al. Among authors: bar on p. J Mol Neurosci. 2004;24(3):343-52. doi: 10.1385/JMN:24:3:343. J Mol Neurosci. 2004. PMID: 15655259 Review.

4

Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy.

Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, Masliah E. Bar-On P, et al. J Neurochem. 2006 Aug;98(4):1032-45. doi: 10.1111/j.1471-4159.2006.04017.x. J Neurochem. 2006. PMID: 16895578 Free article.

5

Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.

Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E. Tsigelny IF, et al. Among authors: bar on p. FEBS J. 2007 Apr;274(7):1862-77. doi: 10.1111/j.1742-4658.2007.05733.x. FEBS J. 2007. PMID: 17381514 Free article.

6

alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease.

Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E. Kawahara K, et al. Among authors: bar on p. J Biol Chem. 2008 Mar 14;283(11):6979-87. doi: 10.1074/jbc.M710418200. Epub 2008 Jan 14. J Biol Chem. 2008. PMID: 18195004 Free article.

7

An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.

Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E. Hashimoto M, et al. Among authors: bar on p. Gene Ther. 2004 Dec;11(23):1713-23. doi: 10.1038/sj.gt.3302349. Gene Ther. 2004. PMID: 15483670

8

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.

Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E. Rockenstein E, et al. Among authors: bar on p. J Neurosci. 2007 Feb 21;27(8):1981-91. doi: 10.1523/JNEUROSCI.4321-06.2007. J Neurosci. 2007. PMID: 17314294 Free PMC article.

9

A montane species treeline is defined by both temperature and drought effects on growth season length.

Bar-On P, Yaakobi A, Moran U, Rozenstein O, Kopler I, Klein T. Bar-On P, et al. Tree Physiol. 2022 Sep 8;42(9):1700-1719. doi: 10.1093/treephys/tpac070. Tree Physiol. 2022. PMID: 35738872

10

Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. Bar-On P, et al. Biochemistry. 2002 Mar 19;41(11):3555-64. doi: 10.1021/bi020016x. Biochemistry. 2002. PMID: 11888271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters